SFL
27.4.2020 18:35:11 CEST | Business Wire | Press release
Regulatory News:
SFL (Paris:FLY):
Consolidated revenue by business segment (€000's) |
|||
|
|
Q1 2020 |
Q1 2019 |
Rental income |
46,638 |
48,504 |
|
o/w |
Paris Central Business District |
39,209 |
40,416 |
|
Paris Other |
6,832 |
7,613 |
|
Western Crescent |
598 |
475 |
Other revenue |
0 |
0 |
|
Total consolidated revenue |
46,638 |
48,504 |
|
First-quarter 2020 consolidated rental income amounted to €46.6 million, down by a slight €1.9 million or 3.8% from the €48.5 million reported for the same period in 2019.
- On a like-for-like basis (excluding all changes in the portfolio affecting period-on-period comparisons), rental income rose by €0.9 million (1.9%), primarily as a result of index increases, and the occupancy rate was stable at around 97% in both periods.
- Rental income from spaces being redeveloped was down by €2.1 million, mainly following the renovation of several floors in the 103 Grenelle and Edouard VII buildings that were vacated in late 2019 and early 2020.
- Lastly, no income from penalties was received in first-quarter 2020, unlike in the same period of 2019 when penalties of €0.6 million were received.
The physical occupancy rate for revenue-generating buildings remained high, at 97.0% at 31 March 2020 (versus 97.4% as of 31 December 2019), while the EPRA vacancy rate stayed low, at 1.9%.
No properties were purchased or sold during the first quarter of 2020.
SFL's consolidated net debt was very slightly higher at 31 March 2020, at €1,740 million (compared with €1,732 million at 31 December 2019), representing a loan-to-value (LTV) ratio of 22.8% based on the portfolio’s appraisal value at 31 December 2019.
The Group’s liquidity position at 31 March 2020 was excellent, with €890 million in undrawn confirmed lines of credit and cash at bank and in hand of €116 million.
Covid-19 health crisis
SFL’s greatest strengths in the current situation are its strategic positioning and low LTV.
It is still difficult to assess the direct and indirect effects of the public health crisis on SFL’s business and results, but all possible measures are being taken to limit the impact and their effectiveness is monitored on a daily basis.
The Group acted swiftly to ensure that all of its properties could remain open and available for use by tenants. The only services no longer available are those that would breach current health measures (mainly mass catering services).
Rental income: SFL is largely unaffected by government measures concerning small retail outlets because of its strategic focus on prime office properties in Paris. The handful of requests received from tenants are analysed on a case-by-case basis and the Group endeavours to support them as far as possible during this difficult period, for example by allowing them to defer payment of their rent for the second quarter of 2020.
Redevelopment and renovation projects: these projects have been halted for the time being, and contractors are currently determining the necessary measures for work to resume, with an ever-present focus on safety conditions. Delivery of the projects will most likely be delayed by a few months due to these disruptions, but while it is too early to make any reliable estimate of the impact of these delays, it is expected to be limited.
Property leasing activities: the rental market has slowed without coming to a complete halt; however, SFL is largely unaffected because it has very few vacant units immediately available for rental. The major property leasing challenges concern the 83 Marceau and Biome properties that are currently being redeveloped and will be delivered in 2021/2022.
A citizen-based approach
To ensure business continuity while also protecting employees, all of SFL’s teams are working from home on full pay, with no temporary lay-offs.
Lastly, SFL has contributed to the collective effort to fight the pandemic, by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people. The Group has also offered to make one of its vacant properties available to the urban affairs ministry to provide emergency housing.
About SFL
Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.
Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA
S&P rating: BBB+ stable outlook
View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release
The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
